The shortage of donor beta cells and the need for strong immunosuppressive drugs to prevent immune attack make beta cell replacement available only to people with severe life-threatening unawareness of their low blood sugar, called hypoglycemia. At JDRF, we are taking a new route to beta cell replacement technologies, with the aim to develop an unlimited source of insulin-producing cells without drugs that limit your immune system’s role in fighting off infection.
One avenue, which Shugo Sasaki, M.D., Ph.D., is pursuing with a postdoctoral fellowship from JDRF, is to use gene editing. More specifically, Dr. Sasaki wants to investigate beta cells that have been edited to make a molecule that attracts “good” immune cells, called regulatory T cells, and whether the transplanted beta cells ar